Compulsory Licensing in the Pharmaceutical Market: History and Practice

In the pharmaceutical industry, the development of a new invention – a drug, the acquisition of a patent and the introduction into civil circulation by the developers spend significant resources in material and time. In this regard, drugs are attractive for falsification, and attempts are also being made to reproduce the imitation of original drugs, which requires special attention to the protection of the rights of patent holders. Obtaining a patent for an invention provides an exclusive right to its owner, being a kind of state gratitude for ensuring innovative progress, and, on the other hand, carries significant threats due to the possible dishonesty of patent owners, which, according to the Author, taking into account the latest challenges of the time, requires no less attention in terms of providing protective mechanisms against abuse. Since the availability of medicines is one of the main tasks of national health care, the Author raised the actual problem of applying one of these mechanisms in domestic law, namely the mechanism for issuing compulsory licenses for medicines as inventions (compulsory licensing). The article contains a brief historical outline of the foreign application of such institutions, analyzes domestic regulation and law enforcement practice, on the basis of which theses are put forward on the need for additional legal regulation.

1. Abashidze A. Kh., Malichenko V. S. Expanding Access to Medicines in Frame of the Right to Enjoy the Benefits of Scientific Progress and Its Applications. Eurasian Law Journal. 2017;5:23-28. (In Russ.).

2. Putilo N. V., Volkova N. S., Tsomartova F. V. The Right of Citizens to Drug Provision. Moscow: Kontrakt Publ.; 2017. 214 p. (In Russ.).

3. Sannikova L. V., Kharitonova Yu. S. Protection of Patent Holders’ Rights Under a Conflict of Drug Patents. Vestnik Permskogo Universiteta. Yuridicheskie Nauki. 2019;43:121-145. DOI: https://doi.org/10.17072/1995-4190- 2019-43-121-145 (In Russ.).

4. Mironova A. I. The Concept of Compulsory License and Licensing in Russian Legislation. Innovations. The Science. Education. 2021;1(44):297-302. (In Russ.).

5. Erokhina E. V. Institute of Compulsory Licensing According to the Legislation of the Russian Federation. Vestnik of the Orenburg State University. 2012;3:45-48. (In Russ.).

6. Losev S. Compulsory Licenses and Access to Medicines. Science and Innovations. 2020;8:58-64. (In Russ.).

7. Shchedrina N. D. The Purpose of Compulsory License in Civil Law. Science and Education: Economy and Financial Economy; Entrepreneurship; Law and Management. 2017;5:62-64. (In Russ.).

8. Salitskaya E. A. Compulsory Licensing of Medicines as a Mechanism for Balancing Public and Private Interests. Vestnik Rossijskoj Akademii Nauk. 2016;86(5):442. DOI: https://doi.org/10.7868/S0869587316050182 (In Russ.).

9. Mironova A. I. Compulsory License in Legislation and Judicial Practice. Matters of Russian and International Law. 2021;11(9A):326-331. DOI: https://doi.org/10.34670/AR.2021.54.14.041 (In Russ.).

10. Kolesnikov D. S., Ugryumov V. M. Dangerous Consequenses of Compulsory Licensing of Patents in the Pharmaceutical Sector. Patents & Licenses. Intellectual Rights. 2015;9:39-51. (In Russ.). 11. Dubovskaya E. V. Compulsory Licensing in WTO: Legal Aspects, Implementation and Potential Lessons for the Russian Federation. Eurasian Law Journal. 2015;2:56-62. (In Russ.).

11. Shakhnazarov B. A. Intellectual Property as a Legal Mechanism Accompanying the Fight Against the Pandemic in the Context of the Spread of Coronavirus Infection (Covid-19). Lex Russica. 2020;73(8):134-147. DOI: https://doi.org/10.17803/1729-5920.2020.165.8.134-147 (In Russ.).

12. Vorozhevich A. S. The Risks and Possible Consequences of the Limitations of Patent Rights in the Pharmaceutical Sector. Courier of the Kutafin Moscow State Law University (MSAL). 2017;6:42-53. DOI: https://doi. org/10.17803/2311-5998.2017.34.6.042-053 (In Russ.).

13. Puchinina M. M. Conditions for Granting Compulsory License for Dependent Invention Use. Actual Problems of Russian Law. 2021;16(11):117-132. DOI: https://doi.org/10.17803/1994-1471.2021.132.11.117-132 (In Russ.).

14. Krupko S. ISubstantive-Legal Criteria “Important Technical Achievement” and “Significant Economic Advantage” in Terms of Application of the Norm of Paragraph 2 of Art. 1362 of the Civil Code of the Russian Federation. Economy and Law. 2020;5:33-51. (In Russ.).

15. Zavyalova M. Compulsory Licensing as Mechanism Exclusion in the Pharmaceutical Sector. Remedium. 2016;12:6-14. DOI: https://doi.org/10.21518/1561-5936-2016-12-6-14 (In Russ.).

16. Mikhailov S. V. The Practice of Compulsory Licensing in the Pharmaceutical Industry. Economy and Law. 2020;10:71-85. (In Russ.).

17. Pazemova E. I. Features of Compulsory Licensing Implementation and Implementation of Other Mechanisms for Restricting Rights of Copyright Holders in the Field of Medicines’. Actual Problems of Russian Law. 2022;17(5):103-115. DOI: https://doi.org/10.17803/1994-1471.2022.138.5.103-115 (In Russ.).

18. Dekhtyar I. N. Problems of Compulsory Licensing of Pharmaceuticals in Connection with Violations of Antitrust Law. Saratov State Law Academy Bulletin. 2022;2:101-110. DOI: https://doi.org/10.24412/2227-7315-2022-2-101-110 (In Russ.).

19. Churilov A. Refusal to Conclude a License Agreement as an Abuse of Dominance: Russian and Foreign Approaches. Economy and Law. 2018;11:63-75. (In Russ.).

20. Matveev A. G. The Patent Law Protection of the Medicinal Products in the Context of the Human Right to Health. In: Koryukina I. P., Karakulova Yu. V., Mishlanov V. Yu., Furman E. G. (Eds.). Modern World, Topical Issues of Bioethics, Molecular and Personalized Medicine. Perm: Perm National Research Polytechnic University Publ.; 2019. P. 109–116. (In Russ.).

21. Lalaev B. Yu., Sachenko A. L. Legal Protection of Medicines. Problematic Questions. In: National Healthcare Innovations. St. Petersburg: Saint Petersburg State Chemical and Pharmaceutical University Publ.; 2018. P. 205–208. (In Russ.).